J. P. Carey was issued 200,233,698 shares on 04/12/2019.

New Post Public Reply Private Reply Replies (0) Message Board
coyote49
487
J. P. Carey was issued 200,233,698 shares on 04/12/2019. From 4/12 to 4/30 only 125.8 million shares traded; a 10.48m daily average. Likely very few of those traded shares were from Carey.

There are 7 notes with past due maturity dates totaling $93,000. We don’t know if any of these have been issued shares since the end of Q2. After those 7 the remaining notes have a 2020 maturity date.

It is my opinion Berman is clearing the above 7 notes. It would explain some of the volume increase and a tanked price per share that can’t seem to recover. There have been a lot of shares issued since 12/11/2018. Hoping once this is complete, we can experience a recovery in price per share.


Shares traded during Q1:

November – 270.0m, 12.85m daily average

December – 350.0m, 18.42m daily average

January – 291.0m, 14.55m daily average

Total Q1 shares traded – 911,000,000, 15.18m daily average

Shares issued for debt conversion: 141,561,726 on 12/11/2018, Carpathia LLC


Shares traded during Q2:

February – 464.3m, 24.43m daily average

March – 516.8m, 24.43m daily average

April – 254.5m, 12.12m daily average

Total Q2 shares traded – 1,235,600,000, 20.25m daily average

Shares issued for debt conversion: 285,237,626, (02/14/2019, 85,003,928 to Carpathia LLC – 04/12/2019, 200,233,698 to J. P. Carey)


Shares traded during Q3 (13 days remaining)

May – 981.4m, 44.6m daily average

June – 753.0m, 37.65m daily average

July – 328.6m, 36.50m daily average

Total Q3 shares traded as of 7/12/2019 – 2,063,000,000, 40.45m daily average

Shares issued for debt conversion: Unknown until release of Q3 filing.

On4 Communications (ONCI) Stock Research Links

ONCI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Lumexa Imaging's Investor Conference Push: Any Real Substance?

Updated Category News Views 132

Lumexa Imaging just dropped a line on Feb 17, 2026, about their upcoming investor conference gigs. Sure, they're strutting into multiple events—Raymond James in Orlando, Leerink Partners in Miami, and Barclays back-to-back days after that. But here’s the kicker: are these talks really worth the buzz? In a space where outpatient imaging claims to be kingpin, you’ve...

Continue Reading
Current Landscape of US Stock Futures Amid Rate Cuts

Updated Category News Views 173

Insights on the Current Stability of U.S. Stock Futures During Asian trading hours, U.S. stock index futures have held steady. Investors are hoping for interest rate cuts as the Federal Reserve's next meeting approaches. This meeting is expected to reveal a significant easing cycle that many in the market are eagerly anticipating. Even with strong reports on consumer and...

Continue Reading
Wispr Flow Revolutionizes Voice Dictation Across Platforms

Updated Category News Views 469

Wispr Flow Expands Its Reach in Voice Dictation Technology In a world where speed and efficiency are paramount, Wispr, known as The Voice Interface Company, is revolutionizing the way we interact with technology. With the recent launch of Wispr Flow for Windows, this innovative voice productivity tool is now accessible to users across both Mac and Windows platforms,...

Continue Reading
MintMiner: Your Ultimate Gateway to Cloud Mining Success

Updated Category News Views 197

Unlocking the Future of Cloud Mining with MintMiner In today's uncertain financial landscape, MintMiner presents an innovative solution for anyone looking to tap into the world of digital assets. As global financial systems face challenges, MintMiner offers a unique platform that makes cloud mining accessible, straightforward, and profitable. Understanding Cloud Mining...

Continue Reading
GT Biopharma's Strategic Move: Withdrawal of S-1 Registration

Updated Category News Views 100

GT Biopharma's Strategic Withdrawal of Form S-1 Registration GT Biopharma, Inc. (NASDAQ: GTBP) recently made headlines with its request for withdrawal of a Form S-1 registration statement. This decision marks a crucial moment for the company, based in San Francisco, known for its innovative approach in the immuno-oncology sector. GT Biopharma focuses on the development of...

Continue Reading